Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation.

Coto-Llerena M, Pérez-Del-Pulgar S, Crespo G, Carrión JA, Martínez SM, Sánchez-Tapias JM, Martorell J, Navasa M, Forns X.

Am J Transplant. 2011 May;11(5):1051-7. doi: 10.1111/j.1600-6143.2011.03491.x. Epub 2011 Apr 5.

2.

Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation.

Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carrillo ED, Berg T, Neuhaus R, Neuhaus P, Neumann UP, Bahra M.

Liver Transpl. 2011 Mar;17(3):289-98. doi: 10.1002/lt.22235.

3.

Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection.

Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ, Heimbach JK, Goldstein D, McHutchison J.

Hepatology. 2011 Jan;53(1):317-24. doi: 10.1002/hep.24074.

4.

Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.

Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, Uchiyama H, Soejima Y, Shirabe K, Matsuura Y, Maehara Y.

Gastroenterology. 2010 Nov;139(5):1577-85, 1585.e1-3. doi: 10.1053/j.gastro.2010.07.058. Epub 2010 Aug 12.

PMID:
20708617
5.

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG.

Gastroenterology. 2010 Jul;139(1):120-9.e18. doi: 10.1053/j.gastro.2010.04.013. Epub 2010 Apr 24.

PMID:
20399780
6.

Donor race does not predict graft failure after liver transplantation.

Asrani SK, Lim YS, Therneau TM, Pedersen RA, Heimbach J, Kim WR.

Gastroenterology. 2010 Jun;138(7):2341-7. doi: 10.1053/j.gastro.2010.02.008. Epub 2010 Feb 19.

7.

The effect of donor race on the survival of Black Americans undergoing liver transplantation for chronic hepatitis C.

Pang PS, Kamal A, Glenn JS.

Liver Transpl. 2009 Sep;15(9):1126-32. doi: 10.1002/lt.21835.

8.

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB.

Nature. 2009 Sep 17;461(7262):399-401. doi: 10.1038/nature08309. Epub 2009 Aug 16.

PMID:
19684573
9.

Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.

de Arias AE, Haworth SE, Belli LS, Burra P, Pinzello G, Vangeli M, Minola E, Guido M, Boccagni P, De Feo TM, Torelli R, Cardillo M, Scalamogna M, Poli F.

Liver Transpl. 2009 Apr;15(4):390-9. doi: 10.1002/lt.21673.

10.

Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C.

Terrault NA, Im K, Boylan R, Bacchetti P, Kleiner DE, Fontana RJ, Hoofnagle JH, Belle SH; VIRAHEP-C Study Group.

Clin Gastroenterol Hepatol. 2008 Dec;6(12):1403-11. doi: 10.1016/j.cgh.2008.08.006. Epub 2008 Aug 19.

11.

Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation.

Berenguer M, Palau A, Aguilera V, Rayón JM, Juan FS, Prieto M.

Am J Transplant. 2008 Mar;8(3):679-87. doi: 10.1111/j.1600-6143.2007.02126.x.

12.

Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus.

Yee LJ, Tang YM, Kleiner DE, Wang D, Im K, Wahed A, Tong X, Rhodes S, Su X, Whelan RM, Fontana RJ, Ghany MG, Borg B, Liang TJ, Yang H; Virahep-C Study Group.

Hepatology. 2007 Jul;46(1):74-83.

PMID:
17526009
13.

Hepatitis C in African Americans.

Pyrsopoulos N, Jeffers L.

J Clin Gastroenterol. 2007 Feb;41(2):185-93. Review.

PMID:
17245218
14.

Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation.

Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, Lampasi F, Tartaglione MT, Marsilia GM, Calise F, Cuomo O, Ascione A.

J Hepatol. 2007 Mar;46(3):459-65. Epub 2006 Nov 27.

PMID:
17196700
15.
16.

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, Brown RS, Belle SH, Hoofnagle JH, Kleiner DE, Howell CD; Virahep-C Study Group.

Gastroenterology. 2006 Aug;131(2):470-7.

PMID:
16890601
17.

Impact of HLA-C and Bw epitopes disparity on liver transplantation outcome.

Bishara A, Brautbar C, Zamir G, Eid A, Safadi R.

Hum Immunol. 2005 Nov;66(11):1099-105. Epub 2006 Mar 15.

PMID:
16571410
18.

Deconstructing the relationship between genetics and race.

Bamshad M, Wooding S, Salisbury BA, Stephens JC.

Nat Rev Genet. 2004 Aug;5(8):598-609. Review. No abstract available.

PMID:
15266342
19.

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR.

Hepatology. 2004 Jun;39(6):1702-8.

PMID:
15185312
20.

A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans.

Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ, Contos MJ, Mills AS, Shiffman ML.

Clin Gastroenterol Hepatol. 2004 Jun;2(6):469-73.

PMID:
15181614
Items per page

Supplemental Content

Write to the Help Desk